nav-left cat-right
cat-right

Harvard’s bone marrow-on-a-chip could replac...

Scientists at Harvard’s Wyss Institute for Biologically Inspired Engineering have unveiled their newest tool for drug testing, dubbed “bone marrow-on-a-chip,” the first device of its kind that mimics the structure, functions and cellular make-up of bone marrow. Bone marrow is made up of complex tissue and has, up until now, primarily been studied intact in living animals. Like the Wyss Institute’s...

Remarkable Twin Study Widens View of Down’s ...

A large coalition of European and American researchers this week published a new gene expression study of trisomy 21, better known as Down’s syndrome, using a novel cellular model of the disorder. Induced pluripotent stem cells were derived from a set of identical twins, only one of which possessed the third copy of chromosome 21 that causes the symptoms of Down’s syndrome. Because identical twins are genetically...

FDA Grants Breakthrough Status to Gene Therapy for...

Celladon became the first company to receive breakthrough status for a gene therapy treatment in development. The treatment, MYDICAR, is intended to reduce the risk of heart failure in patients with a deficiency of the enzyme SERCA2a. The FDA made its decision to grant breakthrough status to MYDICAR on the basis of Celladon’s Phase 1 trial of 39 systolic dysfunction patients. The study reported that subjects receiving...

Coriell Life Sciences Prepares for the Whole-Genom...

When the Coriell Institute launched its Coriell Personalized Medicine Collaborative (CPMC) research project in 2007, its mission was to understand how patients and their physicians react to having genetic information when planning out their health care strategies. The CPMC has now interviewed thousands of participants about their genetic disease risks, and has tended toward the center in debates about how well this...

5th Cancer Targets & Therapeutics Conference ...

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets and therapeutics provide new opportunities for the prevention and treatment of several major disease systems. The 5th Cancer Targets & Therapeutics Conference, taking place on July 7-8, 2014 in Boston, MA will continue to be a premier event for translational researchers, preclinical scientists...

J. Craig Venter’s Human Longevity is about ...

In a media briefing hosted in San Diego, Calif., J. Craig Venter—best known as the man who raced against the international Human Genome Project to assemble the first whole human genome sequence in the early 2000s—today announced the opening of a new commercial company, Human Longevity, Inc., to apply genetic sequencing on a massive scale to some of the most intractable questions about human health and aging. “Thirteen...
Page 3 of 812345...Last »